Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...
Servier looks like it could bring a second IDH inhibitor from its 2021 takeover of Agios’ oncology business to market, after reporting positive results in a phase 3 brain cancer trial.
Ce projet a été rendu possible grâce au soutien financier du Fonds de dotation Mécénat Servier, en collaboration avec Servier Indonésie et Life Project 4 Youth (LP4Y). Albertine Corne (LP4Y ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback